A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Real-World Outcomes of Adult Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Evidence from a Multicenter Retrospective Study.

Ohrakupressur bei Patienten mit Multiplem Myelom - eine randomisierte kontrollierte Studie

International, multicenter, non-interventional PASS study  to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy 

A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma

MYRIAM: Clinical Research platform for molecular testing, treatment and outcome of patients with Multiple Myeloma (Myeloma Registry Platform: MYRIAM)

A Phase I clinical trial to assess safety and tolerability of autologous ROR1 CAR-T cells in ROR1+ tumors